<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04737876</url>
  </required_header>
  <id_info>
    <org_study_id>BMX-02-001</org_study_id>
    <nct_id>NCT04737876</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of BX002-A in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Fecal Pharmacokinetics of Orally Administered BX002-A in Healthy Adult Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BiomX, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BiomX, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of study BMX-02-001 is to evaluate the safety, tolerability and feasibility of&#xD;
      orally administered BX002-A to deliver viable bacteriophages to the gut.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study BMX-02-001 is a randomized, single-blind, placebo-controlled study to evaluate the&#xD;
      safety, tolerability, and feasibility of orally administered BX002-A to deliver viable phages&#xD;
      that can be measured in the stool.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Actual">December 21, 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability: adverse events</measure>
    <time_frame>Through study completion Day 31 (+ 2 days)</time_frame>
    <description>Evaluated by reviewing adverse events</description>
  </primary_outcome>
  <other_outcome>
    <measure>Plaque-Forming Unit analysis</measure>
    <time_frame>Day -1 through Day 6</time_frame>
    <description>Quantitative measurement of viable phage in stool after oral administration of BX002-A via plaque-forming unit analysis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>BX002-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BX002-A: 1 mL liquid for multiple dose oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 1 mL liquid for multiple dose oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BX002-A</intervention_name>
    <description>bacteriophage cocktail</description>
    <arm_group_label>BX002-A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults 18-65 years old&#xD;
&#xD;
          2. Able to understand study procedures and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence or history of clinically significant underlying conditions&#xD;
&#xD;
          2. Women who are pregnant or nursing, or plan to become pregnant during study, or women&#xD;
             of childbearing potential not using adequate contraceptive measures&#xD;
&#xD;
          3. History of constipation, severe diarrhea and/or loose stools within 14 days&#xD;
&#xD;
          4. History of procedures aimed at modifying the gastrointestinal microbiota within past&#xD;
             year (e.g., fecal microbiota transplantation)&#xD;
&#xD;
          5. Topical gastrointestinal treatment (e.g., enemas) in the 2 weeks prior or planned&#xD;
             during study&#xD;
&#xD;
          6. Use of bowel cleansing or preparation in the 4 weeks prior or planned during study&#xD;
&#xD;
          7. Participation in another investigational trial within 30 days&#xD;
&#xD;
          8. Known allergy or hypersensitivity to an excipient in the study drug or placebo&#xD;
&#xD;
          9. Any other reason which according to investigator may impact proper study conduct&#xD;
&#xD;
         10. History of alcohol abuse; drug or medication abuse or tobacco use&#xD;
&#xD;
         11. Subject who cannot be contacted in case of emergency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Physician</last_name>
    <role>Study Director</role>
    <affiliation>BiomX, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

